These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 26710844)

  • 1. Response monitoring in follicular lymphoma by synchronous evaluation of minimal residual disease and diffusion-weighted MRI.
    Meleshko AN; Kharuzhyk SA; Piatrouskaya NA
    Exp Oncol; 2015 Dec; 37(4):295-7. PubMed ID: 26710844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-body MRI-DWI for assessment of residual disease after completion of therapy in lymphoma: A prospective multicenter study.
    Littooij AS; Kwee TC; de Keizer B; Bruin MC; Coma A; Beek FJ; Fijnheer R; Nievelstein RA
    J Magn Reson Imaging; 2015 Dec; 42(6):1646-55. PubMed ID: 25952024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial.
    Galimberti S; Luminari S; Ciabatti E; Grassi S; Guerrini F; Dondi A; Marcheselli L; Ladetto M; Piccaluga PP; Gazzola A; Mannu C; Monitillo L; Mantoan B; Del Giudice I; Della Starza I; Cavalli M; Arcaini L; Tucci A; Palumbo GA; Rigacci L; Pulsoni A; Vitolo U; Boccomini C; Vallisa D; Bertoldero G; Gaidano G; Musto P; Petrini M; Federico M
    Clin Cancer Res; 2014 Dec; 20(24):6398-405. PubMed ID: 25316810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up.
    Papajík T; Jedlicková K; Kriegová E; Jarosová M; Raida L; Faber E; Hubácek J; Vondráková J; Pikalová Z; Indrák K
    Neoplasma; 2001; 48(6):501-5. PubMed ID: 11949845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative assessment of minimal residual disease (MRD) in canine lymphoma by using real-time polymerase chain reaction.
    Yamazaki J; Baba K; Goto-Koshino Y; Setoguchi-Mukai A; Fujino Y; Ohno K; Tsujimoto H
    Vet Immunol Immunopathol; 2008 Dec; 126(3-4):321-31. PubMed ID: 18977540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of different MRI sequences in lesion detection and early response evaluation of diffuse large B-cell lymphoma--a whole-body MRI and diffusion-weighted imaging study.
    Wu X; Nerisho S; Dastidar P; Ryymin P; Järvenpää R; Pertovaara H; Eskola H; Kellokumpu-Lehtinen PL
    NMR Biomed; 2013 Sep; 26(9):1186-94. PubMed ID: 23483722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of clinical status of follicular lymphoma patients after autologous stem cell transplant and quantitative assessment of lymphoma in blood and bone marrow as measured by SYBR Green I polymerase chain reaction.
    Pennell N; Woods A; Reis M; Buckstein R; Spaner D; Imrie K; Hewitt K; Boudreau A; Seth A; Berinstein NL
    J Mol Diagn; 2006 Feb; 8(1):40-50. PubMed ID: 16436633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of t(14;18) by PCR of IgH/BCL2 fusion gene in follicular lymphoma from archived cytological smears.
    Stoos-Veić T; Livun A; Ajduković R; Pejsa V; Jaksić O; Kusec R
    Coll Antropol; 2010 Jun; 34(2):425-9. PubMed ID: 20698113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR.
    Pott C; Brüggemann M; Ritgen M; van der Velden VH; van Dongen JJ; Kneba M
    Methods Mol Biol; 2013; 971():175-200. PubMed ID: 23296964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diffusion-weighted MRI in early chemotherapy response evaluation of patients with diffuse large B-cell lymphoma--a pilot study: comparison with 2-deoxy-2-fluoro- D-glucose-positron emission tomography/computed tomography.
    Wu X; Kellokumpu-Lehtinen PL; Pertovaara H; Korkola P; Soimakallio S; Eskola H; Dastidar P
    NMR Biomed; 2011 Dec; 24(10):1181-90. PubMed ID: 21387451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of whole body MRI and diffusion-weighted MRI in detecting intranodal lesions in patients with lymphoma].
    Li Z; Hu DY; Xia LM; Feng DY; Peng L; Wang CY; Chu Q
    Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):695-8. PubMed ID: 19173913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole-body diffusion-weighted imaging: the added value to whole-body MRI at initial diagnosis of lymphoma.
    Gu J; Chan T; Zhang J; Leung AY; Kwong YL; Khong PL
    AJR Am J Roentgenol; 2011 Sep; 197(3):W384-91. PubMed ID: 21862763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimal residual disease monitoring in early stage follicular lymphoma can predict prognosis and drive treatment with rituximab after radiotherapy.
    Pulsoni A; Della Starza I; Cappelli LV; Tosti ME; Annechini G; Cavalli M; De Novi LA; D'Elia GM; Grapulin L; Guarini A; Del Giudice I; Foà R
    Br J Haematol; 2020 Jan; 188(2):249-258. PubMed ID: 31385309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Very early indicators of response to systemic therapy in lymphoma patients based on alterations in water diffusivity--a preliminary experience in 20 patients undergoing whole-body diffusion-weighted imaging.
    Horger M; Claussen C; Kramer U; Fenchel M; Lichy M; Kaufmann S
    Eur J Radiol; 2014 Sep; 83(9):1655-64. PubMed ID: 24972451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of diffusion-weighted imaging as an adjunct to contrast-enhanced breast MRI in evaluating residual breast cancer following neoadjuvant chemotherapy.
    Hahn SY; Ko EY; Han BK; Shin JH; Ko ES
    Eur J Radiol; 2014 Feb; 83(2):283-8. PubMed ID: 24315957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of diffusion-weighted MRI: predicting axillary lymph node metastases in breast cancer.
    Chung J; Youk JH; Kim JA; Gweon HM; Kim EK; Ryu YH; Son EJ
    Acta Radiol; 2014 Oct; 55(8):909-16. PubMed ID: 24234236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative diffusion weighted MRI: a functional biomarker of nodal disease in Hodgkin lymphoma?
    Punwani S; Prakash V; Bainbridge A; Taylor SA; Bandula S; Olsen OE; Hain SF; Shankar A; Daw S; Humphries P
    Cancer Biomark; 2010; 7(4):249-59. PubMed ID: 21576817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18F-FDG-PET/CT-Controlled Prospective Study in 64 Patients.
    Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Knogler T; Sillaber C; Jaeger U; Simonitsch-Klupp I; Ubl P; Müllauer L; Dolak W; Lukas J; Raderer M
    Clin Cancer Res; 2015 Jun; 21(11):2506-13. PubMed ID: 25733598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes.
    Mosavi F; Wassberg C; Selling J; Molin D; Ahlström H
    Clin Radiol; 2015 Nov; 70(11):1229-36. PubMed ID: 26208992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphomas and glioblastomas: differences in the apparent diffusion coefficient evaluated with high b-value diffusion-weighted magnetic resonance imaging at 3T.
    Doskaliyev A; Yamasaki F; Ohtaki M; Kajiwara Y; Takeshima Y; Watanabe Y; Takayasu T; Amatya VJ; Akiyama Y; Sugiyama K; Kurisu K
    Eur J Radiol; 2012 Feb; 81(2):339-44. PubMed ID: 21129872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.